Defeating tumor resistance,
with Suprabodies
Adherent Health is engineering the next generation of immunotargeted cancer therapies — precision biologics designed to break through resistance mechanisms and restore durable patient response.
The Challenge
Tumors evolve.
Most therapies don't.
Despite remarkable advances in immunotherapy, the majority of patients eventually relapse. Tumors deploy a sophisticated arsenal of resistance mechanisms — antigen escape, immune exclusion, and adaptive signaling — that render today's treatments ineffective.
Adherent Health was founded on a simple conviction: to outpace cancer, we must out-engineer it. Our platform targets the molecular pathways tumors rely on to evade immune detection, designing therapies that adapt as resistance emerges.
Our Approach
Three pillars of next-generation immunotherapy.
Precision Targeting
Multi-specific biologics engineered against tumor-restricted antigens to maximize on-target activity while sparing healthy tissue.
Resistance Adaptation
Therapies designed to anticipate and neutralize the escape mechanisms that drive relapse in conventional immunotherapy.
Durable Response
Restoring sustained immune engagement through novel mechanisms of T-cell recruitment and tumor microenvironment remodeling.
Technology
Built on deep molecular insight.
Our Suprabody engine integrates structural biology, bioconjugate chemistry, and computational modeling to address the molecular signatures that define resistant tumors — and develop the therapeutic levers that can defeat them.
The Company
A team of scientists, clinicians, and builders united by a single mission.
Adherent Health was founded by experts in biopharma discovery and drug development with the belief that the next breakthrough in cancer treatment will come from rigorous biology, courageous engineering, and uncompromising focus.
Partner with us in redefining cancer care.
We're actively engaging with investors, scientific collaborators, and clinical partners. Reach out to learn more.